Zealand Pharma A/S (ZEAL) News
Filter ZEAL News Items
ZEAL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ZEAL News Highlights
- ZEAL's 30 day story count now stands at 11.
- Over the past 23 days, the trend for ZEAL's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- MA, CVR and DK are the most mentioned tickers in articles about ZEAL.
Latest ZEAL News From Around the Web
Below are the latest news stories about ZEALAND PHARMA A that investors may wish to consider to help them evaluate ZEAL as an investment opportunity.
Needham Sticks to Their Buy Rating for Zealand Pharma (ZEAL)E ratio of -4.51. |
Zealand Pharma’s (NASDAQ:ZEAL) Phase 3 SBS Trial Sees Positive ResultsBiotechnology company Zealand Pharma (NASDAQ:ZEAL) has delivered positive topline results from the Phase 3 trial of glepaglutide for the treatment of short bowel syndrome (SBS). The trial met its primary endpoint and the twice-weekly dosing regimen showed a statistically significant decrease in weekly parental support at 24 weeks. The treatment was deemed safe and was well tolerated. |
Total number of shares and voting rights in Zealand Pharma at September 30, 2022Company announcement – No. 42 / 2022 Total number of shares and voting rights in Zealand Pharma at September 30, 2022 Copenhagen, DK and Boston, MA, September 30, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at th |
Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)Company announcement – No. 41 / 2022 Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1) Glepaglutide treatment met the primary endpoint with twice weekly dosing achieving a statistically significant reduction in weekly parenteral support volume by 5.13 Liters/week from baseline at 24 weeks66% of patients in the twice weekly group had a clinically meaningful response (>20% reduction in parenteral support volume)In total 9 pa |
Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)Press release – No. 6 / 2022 Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) BI 456906 effectively lowered HbA1c up to -1.88% at week 16 in patients with type 2 diabetes in the Phase 2 clinical trialPreclinical pharmacology of BI 456906 supports ongoing Phase 2 studies in obesity or non-alcoholic steatohepatitis Copenhagen, Denmark and Boston MA, U.S. September 21, 2022 – Zealand Phar |
Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE MeetingPress release – No. 5 / 2022 Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting Dasiglucagon significantly reduced the requirement for intravenous glucose to maintain glycemia in newborns and infants with CHI (Part 1 of Phase 3 trial)Dasiglucagon reduced time in hypoglycemia and enabled discontinuation of intravenous glucose in most infants and limited the need for pancreatectomy (Part 2 of Phase 3 trial)Results support t |
Zealand Pharma grants warrants to employees in DenmarkCompany announcement – No. 40 / 2022 Zealand Pharma grants warrants to employees in Denmark Copenhagen, DK and Boston, MA, September 13, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces granting of warrants to employees in accordance with Zealand's Remuneration policy and overall guidelines for incentive pay, as adopted at the annual genera |
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee WarrantsCompany announcement – No. 39 / 2022 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, DK and Boston, MA, September 8, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 7,802 divided into 7,802 new shares with a nominal value of DKK 1 each |
Zealand Pharma to Participate in Morgan Stanley 20th Annual Global Healthcare ConferencePress release – No. 4/ 2022 Zealand Pharma to Participate in Morgan Stanley 20th Annual Global Healthcare Conference Copenhagen, DK and Boston, MA, September 7, 2022 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference. Morgan Stanley 20th Annual Glo |
Zealand Pharma, Novo Nordisk Ink Licensing Pact For Drug To Lower Blood Sugar LevelsZealand Pharma A/S (NASDAQ: ZEAL) has entered into a global license and development agreement with Novo Nordisk A/S (NYSE: NVO) to commercialize Zegalogue (dasiglucagon) for injection. FDA approved Zegalogue for severe hypoglycemia in pediatric and adult patients with diabetes aged six and above. Under the terms of the agreement, Zealand will receive an upfront payment of DKK 25 million and is eligible to receive up to DKK 45 million in near-term development, regulatory, and manufacturing-based |